Great thread, thanks for highlighting. Still do not understand why it is almost verboten to discuss the issue of boosters in people who have received J&J vaccine and provide guidance backed by the available evidence on what to do with these individuals.
-
-
Not too soon for a policy statement. I am getting this question more frequently from individuals who got the J&J vaccine or their providers. Clinicians would feel more confident in the advice they give if this is backed by a policy statement grounded win science from PH agencies.
1 reply 0 retweets 8 likes -
I’m struggling a little to understand this one. Why recommend re-vaccinating 10 mill+ people when there is a global scarcity of vaccine and J&J protects severe disease against variants? If it’s transmission risk why not use those resources for unvaccinated pockets in the South?
2 replies 1 retweet 3 likes -
Or why not do both? i.e assess need to re-vaccinate those who got J&J already and offer them a booster while continuing to vaccinate pockets of the south where vaccination is low. I think there's a need for clarity on booster; are they needed? If yes when and with what.
3 replies 0 retweets 5 likes -
But how do we assess the need to re-vaccinate an individual after vaccination? We don’t have correlates published (ahem,
@moderna_tx), and 6 month data is only now coming out. I’m not convinced we will need boosters at all, and if so, not before 1 year.2 replies 0 retweets 1 like -
Replying to @k_stephensonMD @PaulSaxMD and
It will be nice to have resources to back any answer I provide to a patient who received J&J vaccine and is asking about whether they need a booster or not. Right now there is a lot of guessing and tbh confusion and a bit of anxiety.
3 replies 0 retweets 4 likes -
Replying to @Boghuma @PaulSaxMD and
Agreed! Working on that 6 month immuno data now Dr. Titanji! We will get it to you ASAP
In all seriousness, I know the anxiety is real, so not downplaying. What would be helpful is the (overdue) correlates analysis from Moderna and Pfizer.1 reply 0 retweets 3 likes -
Replying to @k_stephensonMD @PaulSaxMD and
I appreciate all the work you and your team have put in on the vaccine front. Literally saved thousands of lives. I look forward to seeing the data and yes agree on the need to see moderna and pfizer correlates of protection data as well.
1 reply 0 retweets 1 like -
Replying to @Boghuma @PaulSaxMD and
Thanks :) I always feel obligated to say that I have no financial COI for J&J and like a mom, I just want it to be happy and do well in the world. But if we had to boost any of them in the US, it would be J&J.
1 reply 0 retweets 2 likes -
Replying to @k_stephensonMD @Boghuma and
Question is - why a J&J boost? Efficacy against Delta? Or efficacy is lower in general?
2 replies 0 retweets 0 likes
zeynep tufekci Retweeted Michael Lin, MD PhD 🧬
Symptomatic breakthrough rates, question remains open but there are some things to look at. See here:https://twitter.com/michaelzlin/status/1407059999101181955 …
zeynep tufekci added,
-
-
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.